Medicus Pharma Secures $22.9M in Secured Debt, Providing Critical Lifeline Amidst Delisting Threat
MDCX sits 23% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
Medicus Pharma has secured up to $22.9 million in secured notes from Streeterville Capital, with $12 million received at closing and a net cash infusion of approximately $17 million. This financing provides a critical lifeline for the company, which is facing severe financial distress, including a going concern warning from auditors and a Nasdaq delisting notice. The capital will fund clinical development and general corporate purposes, buying the company time despite the high cost of the debt. This follows an 8-K filed minutes earlier disclosing the same debt and a series of highly dilutive ATM offerings. The company is also seeking shareholder approval for a reverse stock split to address its Nasdaq listing deficiency.
At the time of this announcement, MDCX was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5M. The 52-week trading range was $0.25 to $7.73. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.